M&A / Deals

Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact

Pharmaceutical Technology

Eli Lilly and Profluent will harness AI to discover and develop recombinases for precise, large-scale gene editing.

Read full story

pharminent April 29, 2026 (Last updated: April 29, 2026)

Pharmaceutical Technology

Eli Lilly and Profluent will harness AI to discover and develop recombinases for precise, large-scale gene editing.

Read full story